SUNRISE is a double-blind phase 3 trial across 63 sites in 12 countries testing whether tezepelumab reduces maintenance oral corticosteroids while preserving asthma control. Interpretation should integrate overall and eosinophil subgroups, exacerbations and safety.
Key findings
- SUNRISE is a double-blind phase 3 trial across 63 sites in 12 countries testing whether tezepelumab reduces maintenance oral corticosteroids while preserving asthma control. Interpretation should integrate overall and eosinophil subgroups, exacerbations and safety.
Why this matters globally
This work adds internationally comparable evidence in Health sciences and defines questions for replication in other populations or systems. Its global value lies in the evidence and transferable reasoning, not in a single impact score.
Thai researcher contribution
Thailand-linked authors and Hatyai Hospital contribute to the research network behind this work. Thai participation is identified from bibliographic affiliations and should be checked against the author list and source article.
Limitations to consider
Eligibility can limit generalisability; long-term and real-world outcomes remain important, and secondary or subgroup findings should not be overinterpreted.